Web Exclusives

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.

Disparities Remain in Prevalence of Cancer Screening Tests

Disparities Remain in Prevalence of Cancer Screening Tests

Disparities persist in recommended cancer screening tests among U.S. adults, particularly among the uninsured.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.

Combined Digital Screening Best for Detecting Breast Cancers

Combined Digital Screening Best for Detecting Breast Cancers

Digital mammography and tomosynthesis proved superior to digital mammography alone, according to a study.

Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer

Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer

Researchers conducted a retrospective analysis to determine the impact of inflammatory responses in patients with ovarian cancer undergoing first-line chemotherapy with or without bevacizumab.

Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma

Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma

In a systematic review, researchers explored the financial burden of treating grade 3 to 4 adverse events associated with melanoma and its treatment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs